摘要
目的分析对慢性胃炎使用埃索美拉唑、左氧氟沙星和奥硝唑联用治疗的效果。方法60例慢性胃炎患者,随机分为观察组(31例)和对照组(29例)。对照组患者采用埃索美拉唑、阿莫西林和克拉霉素治疗,观察组患者采用埃索美拉唑、左氧氟沙星和奥硝唑联用治疗。比较两组治疗前后肿瘤坏死因子-α(TNF-α)、白细胞介素-8(IL-8)、白细胞介素-6(IL-6)水平;治疗效果;幽门螺杆菌清除率、幽门螺杆菌清除时间、复发率和治疗成本;不良反应发生情况。结果治疗后,两组患者TNF-α、IL-8、IL-6水平均低于本组治疗前,且观察组患者TNF-α、IL-8、IL-6水平均低于对照组,差异均具有统计学意义(P<0.05)。观察组患者的治疗总有效率87.10%显著高于对照组的62.07%,差异具有统计学意义(P<0.05)。观察组幽门螺杆菌清除率100.00%高于对照组的79.31%,复发率3.23%低于对照组的24.14%,幽门螺杆菌清除时间(4.48±1.06)d短于对照组的(6.92±2.13)d,差异均具有统计学意义(P<0.05);两组治疗成本比较差异无统计学意义(P>0.05)。观察组患者的不良反应发生率为6.45%,显著低于对照组的27.59%,差异具有统计学意义(P<0.05)。结论慢性胃炎患者使用埃索美拉唑、左氧氟沙星和奥硝唑联用治疗,可以有效减轻炎症,有效的清除幽门螺杆菌,治疗效果显著,安全性高,复发率低,疗效确切,具有临床应用的价值。
Objective To analyze the therapeutic effect of esomeprazole and levofloxacin combined with ornidazole in the treatment of chronic gastritis.Methods A total of 60 chronic gastritis patients were randomly divided into observation group(31 cases)and control group(29 cases).The control group was treated by esomeprazole and amoxicillin combined with clarithromycin,and the observation group was treated by esomeprazole and levofloxacin combined with ornidazole.The tumor necrosis factor-α(TNF-α),interleukin-8(IL-8),interleukin-6(IL-6)levels before and after treatment,therapeutic effect,Helicobacter pylori clearance rate,Helicobacter pylori clearance time,recurrence rate and treatment cost and occurrence of adverse reactions were compared between the two groups.Results After treatment,the levels of TNF-α,IL-8 and IL-6 of the two groups were lower than those before treatment,and the the levels of TNF-α,IL-8 and IL-6 of the observation group were lower than those of the control group,and the difference was statistically significant(P<0.05).The total effective rate of treatment 87.10%of the observation group was significantly higher than that of the control group 62.07%,and the difference was statistically significant(P<0.05).The Helicobacter pylori clearance rate 100.00%of the observation group was higher than that of the control group 79.31%,recurrence rate 3.23%was lower than that of the control group,and Helicobacter pylori clearance time(4.48±1.06)d was shorter than that of the control group(6.92±2.13)d.The difference was statistically significant(P<0.05).There was no statistically significant difference in treatment cost between the two groups(P>0.05).The incidence of adverse reactions of the observation group was 6.45%,which was significantly lower than that of the control group 27.59%,and the difference was statistically significant(P<0.05).Conclusion Esomeprazole and levofloxacin combined with ornidazole shows remarkable effect in the treatment of chronic gastritis patients,which can effectively reduce inflammation and eliminate Helicobacter pylori with high safety,low recurrence rate and definite curative effect.It has clinical application value.
作者
胡志方
HU Zhi-fang(Department of Gastroenterology,People’s Hospital Pukou Branch,Nanjing 211800,China)
出处
《中国实用医药》
2020年第20期27-29,共3页
China Practical Medicine
关键词
慢性胃炎
幽门螺杆菌
埃索美拉唑
左氧氟沙星
奥硝唑
炎症反应
Chronic gastritis
Helicobacter pylori
Esomeprazole
Levofloxacin
Ornidazole
Inflammatory response
